HopeStage
Back to overview

Depression studies

Topics
More filters

Depression

Depression involves persistent low mood or loss of interest, often with tiredness and changes in sleep or appetite.

7264studies shown
Showing 1,537-1,548 of 7,264
Device study icon
CompletedNCT07059143

6 Weeks Right-Amygdala TIS for Depression

Official study title

A Multicenter Randomized Double-Blind Controlled Trial of Six-Week Transcranial Temporal Interference Stimulation(TIS) Targeting the Right Amygdala for Rapid Alleviation of Depressive Symptoms.

This study has finished and is no longer accepting participants.

Multiple locations, including Guangdong
DepressionDevice studyAges 18–60
Countries
China
Sponsor
Ruijin Hospital
Other study type icon
CompletedNCT01344733

A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD)

Official study title

A Non - Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient Diagnosed as With Treatment Resistant Major Depressive Disorder (MDD)

This study has finished and is no longer accepting participants.

Multiple locations, including Agrigento
Depression, BipolarityObservational studyAges 18–65
Countries
Italy
Sponsor
AstraZeneca
Drug study icon
CompletedNCT07549581

SEP-380135 in Adults With Schizophrenia or Major Depressive Episode

Official study title

A Phase 1b, Randomized, Double-blind, Placebo-controlled Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of SEP-380135 in Adults With Schizophrenia or With a Major Depressive Episode Associated With Bipolar I or II Disorder or Major Depressive Disorder

This study has finished and is no longer accepting participants.

In Los Alamitos
Depression, Schizophrenia, ...Medication studyAges 18–55
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
Drug study icon
WithdrawnNCT06735079

REL-1017 for depression

Official study title

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 As Adjunctive Treatment for Major Depressive Disorder (MDD)

This study was withdrawn before enrollment.

Multiple locations, including Milan
DepressionMedication studyAges 18–65
Countries
Switzerland, Italy
Sponsor
MGGM LLC
Drug study icon
CompletedNCT07253207

Levomilnacipran Hydrochloride Extended-Release Capsules for depression

What is this study about?

This study evaluated the safety and effectiveness of Levomilnacipran Hydrochloride Extended-Release Capsules for people with depression.

This study has finished and is no longer accepting participants.

Multiple locations, including Hefei
DepressionMedication studyAges 18–65
Countries
China
Sponsor
Zhejiang Huahai Pharmaceutical Co., Ltd.

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.